Children's Health Defense Petitions FDA to Revoke COVID-19 Vaccine Licenses Over Regulatory Compliance Concerns
Key Insights
Children's Health Defense (search) filed a citizen petition requesting FDA revoke Biologics License Application approval for Pfizer's Comirnaty and Moderna's Spikevax COVID-19 (search) vaccines.
The petition alleges FDA violated regulatory standards by granting full licensure without requiring manufacturers to meet typical BLA compliance requirements including proper clinical investigations.
CHD claims the vaccines transitioned from Emergency Use Authorization to full licensure without meeting legally required components such as Institutional Review Board oversight and validated manufacturing processes.
Children's Health Defense (search) (CHD) has filed a formal citizen petition with the U.S. Food and Drug Administration requesting the revocation of Biologics License Application (BLA) approval for all Pfizer-BioNTech and Moderna COVID-19 (search) vaccines. The petition, submitted on December 8 to FDA Commissioner Martin A. Makary, alleges that the agency violated its own regulatory standards when granting full licensure to these mRNA vaccines.
Regulatory Violations Alleged
The petition, based on research by pharmaceutical industry veteran Sasha Latypova, claims the FDA allowed the vaccines to "jump tracks" from Emergency Use Authorization (EUA) status to full BLA licensure without requiring proper compliance with standard regulatory requirements. According to CHD CEO Mary Holland, a co-author of the petition, "The FDA granted full licensure to these vaccines without requiring the manufacturers to meet the legal standards that typically govern licensed vaccines."
The organization alleges that during Operation Warp Speed, the FDA waived critical, legally required components of BLA compliance, including Institutional Review Board (IRB) oversight, documented informed consent, validated manufacturing processes, good laboratory practice in preclinical testing, and representative clinical trial data.
Manufacturing and Clinical Trial Concerns
The petition cites leaked European Medicines Agency (search) (EMA) documents from late 2020, documented by The BMJ, which indicate that European regulators issued "three Quality Major Objections" to Pfizer's manufacturing process. These documents revealed discrepancies between the material used in Phase 3 clinical trials and the final commercial product.
Additional concerns outlined in the petition include:
- Pfizer's trial data cannot lawfully serve as the basis for BLA labeling because clinical-trial batches were produced through a different process than commercial batches
- Clinical trials had large data gaps, lacked clear efficacy endpoints, and participants were unblinded
- Both manufacturers initiated human testing before completing required nonclinical assessments
- Toxicology and biodistribution studies didn't follow Good Laboratory Practices and sometimes relied on surrogate mRNA constructs
Current Vaccine Status and Labeling Changes
Since receiving BLA licensure, both vaccines have undergone substantial label revisions with indication and usage restrictions. The companies were required to add warnings for myocarditis (search) and pericarditis (search). Currently, Moderna's Spikevax is licensed for adults age 65 and older, and for everyone 6 months to 64 years old who has at least one underlying condition that puts them at high risk for severe COVID-19 (search) outcomes. Pfizer's shot is licensed for adults 65 and older, and people ages 5 through 64 with at least one underlying condition.
Legal Framework and Emergency Declaration
The petition distinguishes between EUA and BLA regulatory pathways, noting that "EUA products are deployed on the market based on only a 'may be effective' opinion of the HHS Secretary and are not subject to formal product recall procedures." In contrast, BLA requires submission of comprehensive applicant information, product/manufacturing information, pre-clinical studies, clinical studies, and labeling that meets purity, potency, safety, efficacy, manufacturing compliance, and labeling disclosure standards.
Latypova emphasized that "U.S. law permits EUA products to be adulterated and misbranded under the PREP Act declaration of public health emergency," but noted that "misbranding BLA products is a severe violation of federal law."
Call for Public Engagement
The petition requests that the FDA properly designate the vaccines as EUA products for as long as the Department of Health and Human Services Declaration of Emergency remains in effect, which is currently set to last until the end of 2029. CHD is calling on the public, including healthcare workers, parents, and military members, to submit comments supporting the petition on the FDA's website.
Attorney Ray Flores, outside counsel to CHD and petition signatory, stated the petition should "become the focal point for exposing COVID-19 (search) vaccines," noting that people can upload comments with supporting documents or voice support with personal anecdotes.
The FDA is obligated to review the petition and respond within 180 days, though the agency may extend that timeline. Holland called for public support, stating, "I hope the public will join the call for the agency to fulfill its critical mission and that the FDA will remove the licenses, and restore the EUA for these products if it chooses to keep them on the market."